141 related articles for article (PubMed ID: 21294246)
1. Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).
Giraldi E; Provenzi M; Fiocchi R; Colledan M; Cornelli P; Torre G; Rambaldi A; Conter V
Pediatr Blood Cancer; 2011 Aug; 57(2):324-8. PubMed ID: 21294246
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
4. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
5. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
Mamzer-Bruneel MF; Lomé C; Morelon E; Levy V; Bourquelot P; Jacobs F; Gessain A; Mac Intyre E; Brousse N; Kreis H; Hermine O
J Clin Oncol; 2000 Nov; 18(21):3622-32. PubMed ID: 11054435
[TBL] [Abstract][Full Text] [Related]
6. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
[TBL] [Abstract][Full Text] [Related]
7. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
[TBL] [Abstract][Full Text] [Related]
8. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses.
Majewski M; Korecka M; Joergensen J; Fields L; Kossev P; Schuler W; Shaw L; Wasik MA
Transplantation; 2003 May; 75(10):1710-7. PubMed ID: 12777861
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Williams KM; Higman MA; Chen AR; Schwartz CL; Wharam M; Colombani P; Arceci RJ
Pediatr Blood Cancer; 2008 Mar; 50(3):667-70. PubMed ID: 17318876
[TBL] [Abstract][Full Text] [Related]
12. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Trappe RU; Choquet S; Reinke P; Dreyling M; Mergenthaler HG; Jäger U; Kebelmann-Betzing C; Jonas S; Lehmkuhl H; Anagnostopoulos I; Leblond V; Hetzer R; Dörken B; Riess H; Oertel S
Transplantation; 2007 Dec; 84(12):1708-12. PubMed ID: 18165786
[TBL] [Abstract][Full Text] [Related]
13. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
[TBL] [Abstract][Full Text] [Related]
14. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.
Orjuela M; Gross TG; Cheung YK; Alobeid B; Morris E; Cairo MS
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3945S-52S. PubMed ID: 14506193
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination.
Gupta S; Fricker FJ; González-Peralta RP; Slayton WB; Schuler PM; Dharnidharka VR
Pediatr Transplant; 2010 Nov; 14(7):896-902. PubMed ID: 20642490
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma.
Kumar R; Galardy PJ; Dogan A; Rodriguez V; Khan SP
Pediatr Blood Cancer; 2011 Aug; 57(2):317-20. PubMed ID: 21462303
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.
Fohrer C; Caillard S; Koumarianou A; Ellero B; Woehl-Jaeglé ML; Meyer C; Epailly E; Chenard MP; Lioure B; Natarajan-Ame S; Maloisel F; Lutun P; Kessler R; Moulin B; Bergerat JP; Wolf P; Herbrecht R
Br J Haematol; 2006 Sep; 134(6):602-12. PubMed ID: 16889621
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience.
Marino D; Burra P; Boccagni P; Calabrese F; Canova F; Trentin C; Boso C; Soldà C; Angeli P; Aversa SM
Anticancer Res; 2010 Jun; 30(6):2383-91. PubMed ID: 20651397
[TBL] [Abstract][Full Text] [Related]
20. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C
Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
